Register entry
Milestone Pharmaceuticals USA, Inc.
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 6
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
6| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10010522 | CARDAMYSTetripamil | use | Jun 2028 |
| 10010523 | CARDAMYSTetripamil | substance | Jun 2028 |
| 9227918 | CARDAMYSTetripamil | product | Jun 2028 |
| 9463179 | CARDAMYSTetripamil | use | Jun 2028 |
| 10117848 | CARDAMYSTetripamil | product | Apr 2036 |
| 12257224 | CARDAMYSTetripamil | use | Jul 2042 |
| Product | Exclusivity | Until |
|---|---|---|
| CARDAMYSTETRIPAMIL | NCE New chemical entity | Dec 2030 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Cardamyst | etripamil | spray, nasal | 83468-070NDA |
Enquiry
Common questions
- Is Milestone Pharmaceuticals USA, Inc. FDA approved?
- Milestone Pharmaceuticals USA, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Milestone Pharmaceuticals USA, Inc. make?
- 1 product is listed under Milestone Pharmaceuticals USA, Inc. in the openFDA NDC Directory, most often as spray. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.